Clinical Trials Logo

Fever clinical trials

View clinical trials related to Fever.

Filter by:

NCT ID: NCT05450770 Not yet recruiting - HIV Infections Clinical Trials

Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination

NCT ID: NCT05332197 Not yet recruiting - Yellow Fever Clinical Trials

Booster Vaccine for Yellow Fever

BoVY
Start date: May 16, 2022
Phase: Phase 3
Study type: Interventional

This is a phase III trial on Children. The investigators will enroll a total of 750 participants in Fajikunda Health Center (Gambia) The aims of the study are - To describe the safety and immunogenicity of a booster dose of a licensed yellow fever vaccine administered to 3 different age cohorts of children, following a documented primary dose of a yellow fever vaccine administered at nine-months of age. - To characterise the rate of yellow-fever PRNT sero-reversion (seropositive to seronegative) over a period of 9 months to 8 years following a single primary dose of yellow fever vaccine administered to Gambian infants at nine months age. - To profile the immune response to the booster dose of YF vaccine in order to explore underlying mechanisms for longevity of vaccine-induced antibody.

NCT ID: NCT05302739 Not yet recruiting - Hyperthermia Clinical Trials

The Effects of Facial Cooling on Fencing Performance

Start date: April 20, 2022
Phase: N/A
Study type: Interventional

Fencing competitions can last between nine and eleven hours, during which athletes wear layers of protective equipment that impair evaporative heat transfer and spend a large amount of time at exercise intensities > 85% maximum heart rate. Fencing performance can potentially contribute to heat stress due to increases in core temperature. Elevated core temperatures could hamper performance, and therefore the implementation of a strategy to reduce core temperature increases could lead to augmented fencing performance. Cooling methods are limited for use between fencing matches and during short breaks within a direct elimination match. Furthermore, due to multiple layers of thick protective equipment cooling method applications are limited primarily to the facial area. A potential cooling strategy, during fencing competition, includes the utilization of a water facial mist spray combined with fanning of the face. Therefore, the aim of this study is to investigate the novel use of facial cooling on core temperature, relevant physiological parameters, perceived exertion and thermal comfort and sensation during a simulated fencing competition performance, in male epee fencers.

NCT ID: NCT05282784 Not yet recruiting - Solid Tumor Clinical Trials

Hyperthermia With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

The main purpose of this study is to evaluate immunogenic effect of hyperthermia applied with flexible electrode-typed 2-MHz device during radiotherapy for solid tumors.

NCT ID: NCT05206006 Not yet recruiting - Febrile Neutropenia Clinical Trials

Impact of Computerized Decision Support for ANTIBIOtic Prescription in Cancer Patients With Febrile NEutropenia in the Emergency Department on Treatment Failure.

ANTIBIONEED
Start date: February 14, 2022
Phase: N/A
Study type: Interventional

Treatment of patients with febrile neutropenia (FN) attending Emergency Departments (EDs) relies on rapid antibiotic initiation in order to control a presumed infection. The choice of initial antibiotics is empirical and depends on patient's prior colonization or infection by multi-drug resistant pathogens (MDRPs) and risk stratification. Stratification of high-risk patients needing broad-spectrum antibiotics is debated. Thus, for non-specialist physicians, this choice may be challenging, leading to inappropriate initial antimicrobial regimens, potential risks for the patient and higher costs. Furthermore, international guidelines recommended to develop antibiotic stewardship programs and promoted an initial strategy based on escalation or de-escalation approaches, with early reassessment depending on patients' clinical course and microbiological results. Nevertheless, this interesting strategy may increase the level of complexity for the choice of the initial antibiotic regimen by non-specialist emergency physicians who are often the first prescribers in this context. We developed an interactive computerized decision support app (CDSA) for initial antibiotic prescription and early revaluation in patients with FN. The first goal of this app is to assist non-specialized physicians in choosing initial antimicrobial regimen for patients with FN when they attend EDs. It uses an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the app is also designed to propose an algorithm of antibiotic revaluation at day 3-4 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines. We hypothesize that such a CDSA may improve the adherence to guidelines for the choice of initial antibiotic regimen for FN in the ED, favour early antibiotic reassessment for hospitalized patients, both decreasing the risk of treatment failure.

NCT ID: NCT05108545 Not yet recruiting - Clinical trials for Neutropenia and Fever

A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever

Start date: December 15, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label, single-arm, phase III study to evaluate the safety and efficacy of Amphotericin B liposomes in patients with persistent neutropenia and fever.

NCT ID: NCT05070832 Not yet recruiting - Radiotherapy Clinical Trials

Hyperthermia Combined With Neoadjuvant Radiochemotherapy for LARC

PUTHRC-001
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether adding deep hyperthermia to neoadjuvant concurrent radiochemotherapy could improve T-downstaging rate for locally advanced rectal cancer (LARC).

NCT ID: NCT05034809 Not yet recruiting - Clinical trials for Dengue Fever With Warning Signs

Effectiveness Of High Dose Melatonin As Adjunctive Therapy For Dengue Fever With Warning Signs

Start date: October 20, 2021
Phase: Phase 2
Study type: Interventional

Dengue Hemorrhagic Fever is a mosquito-borne viral disease endemic in the Philippines which caused multiple epidemics. Most points to the activation of the complement system secondary to humoral respond leading to cytokine release causing systemic inflammation. Melatonin, is a hormone which has an a) anti-viral, b) immunomodulator, c) antioxidant, d) modulatory effect on hematopoiesis and e) anti-inflammatory action. This is a randomized control trial to determine the effectiveness of adjunctive melatonin therapy among patients diagnosed with Dengue fever with Warning Signs. This would include children aged 5 to 18 years old with no signs of hemmorhagic shock. They would be randomly assigned into 2 groups. Baseline Complete blood count with platelet (CBCPC) will be collected. Daily CBCPC will be collected and would be statistically analyze after the study.

NCT ID: NCT05008458 Not yet recruiting - Febrile Seizure Clinical Trials

Value of Von Willebrand Factor and Copeptin Assay in Children With Febrile Seizures at Sohag University Hospital

Start date: September 1, 2021
Phase:
Study type: Observational

Febrile seizures are one of the most common clinical diseases in pediatric neurology. It occurs between 6 months and 6 years of age and occurs in ~2-5% of children. According to the age, frequency, duration, and type of seizures FS is divided into simple febrile seizures and complex febrile seizures Differentiation between febrile seizures and non-ictal events associated with fever such as shivering or dizziness is challenging. Therefore, precise diagnosis of FS after paroxysmal episodes associated with fever is often hindered by the lack of an objective biomarker With the widespread application of technologies, such as molecular biology, in medicine, some biomarkers for predicting or diagnosing FS have attracted attention. Imuekemhe et al in 1989 and 1996 found that lactic acid in the serum and cerebrospinal fluid of children with FS was significantly increased . Arginin-vasopressin hormone AVP released by the pituitary gland, has been shown to be involved in the thermoregulatory response to fever and convulsions Although AVP is unstable in the peripheral blood and, therefore, unsuited for diagnostic use the C-terminal portion of the AVP precursor copeptin has been recognized as a robust marker of AVP secretion . Wellman et al. found that the serum copeptin and Von Willebrand factor of children with FS were significantly higher than those of the control group .

NCT ID: NCT04889742 Not yet recruiting - Prostate Cancer Clinical Trials

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors

HETERERO
Start date: May 10, 2024
Phase: Phase 2
Study type: Interventional

This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.